Li Zhang

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Keunchil Park, Eng-Huat Tan, Kenneth J. O’Byrne et al. · The Lancet Oncology · 2016 · 1.1K citations

Oncology, Phase 2B, Pathology +8

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

Nan Chen, Wenfeng Fang, Jianhua Zhan et al. · Journal of Thoracic Oncology · 2015 · 672 citations · Full text

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

Baohui Han, Kai Li, Qiming Wang et al. · JAMA Oncology · 2018 · 591 citations · Full text

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

Li Zhang, Yan Huang, Shaodong Hong et al. · The Lancet · 2016 · 515 citations

Cisplatin Versus Fluorouracil, Medicine, Metronomic Therapy +6

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

Wenfeng Fang, Yunpeng Yang, Yuxiang Ma et al. · The Lancet Oncology · 2018 · 495 citations

Medicine, Immunology, Pathology +8